Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03826030 · ClinicalTrials.gov registry record · Phase 2

Transcranial Direct Current Stimulation for Post-stroke Motor Recovery

A Phase 2 study of Stroke, Ischemic and Motor Activity, sponsored by Duke University.

Completed
Registry status
Phase 2
Development phase
129
Enrollment target
14
Study locations

NCT03826030: Completed Phase 2 study of Stroke, Ischemic and Motor Activity, sponsored by Duke University.

NCT03826030 is a Phase 2 study of Stroke, Ischemic and Motor Activity that has completed, run by Duke University. The registered enrollment target is 129 participants, below the 286-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (55% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03826030, a Phase 2 study of Stroke, Ischemic and Motor Activity, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 2
Development phase
129 participants
Enrollment target
14
Study locations

Study Summary

This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation technique is called transcranial direct current stimulation (tDCS). The treatment uses direct currents to stimulate specific parts of the brain affected by stroke. The adjunctive rehabilitation therapy is called "modified Constraint-Induced Movement Therapy" (mCIMT). During this therapy the subject will wear a mitt on the hand of the arm that was not affected by a stroke and force to use the weak arm. The study will test 3 different doses of brain stimulation in combination with mCIMT to find out the most promising one.

Primary Outcome

The Fugl-Meyer Upper-Extremity (FM-UE) is a measure of motor impairment (0 to 66 points, with higher points indicating less impairment). FM-UE scale consists of a 33-item assessment which provides a global assessment of UE motor impairment. A rater provides an ordinal rating (2=near normal ability/response, 1=partial ability, 0=unable to perform/no response). The FM-UE scale is a proven scale with excellent intra-rater reliability (0.99), inter-rater reliability (0.99), test-retest reliability (

Interventions

  • DEVICE Sham
  • DEVICE Low dose tDCS
  • DEVICE High dose tDCS
  • BEHAVIORAL mCIMT

Study Locations (14)

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Cleveland VA Medical Center - Cleveland

Pennsylvania

  • Moss Rehabilitation Research Institute - Elkins Park
  • University of Pittsburgh Medical Center Presbyterian Hospital - Pittsburgh

Alabama

  • University of Alabama at Birmingham Hospital - Birmingham

California

  • Keck Hospital of USC - Los Angeles

District of Columbia

  • MedStar National Rehabilitation Hospital - Washington D.C.

Georgia

  • Emory Rehabilitation Hospital - Atlanta

Kentucky

  • Cardinal Hill Rehabilitation Hospital - Lexington

Massachusetts

  • Baystate Medical Center - Springfield

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2019-09-01
Est. Completion 2024-09-19
Phase Phase 2
Duke University

1,725 total trials

What the finished NCT03826030 record still lists

NCT03826030 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 286-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (55% lower).

The record links to 3 conditions, with Stroke, Ischemic appearing as the primary indexed condition, and to 4 interventions - of which Sham is the first listed.

NCT03826030 lists 14 locations in 12 states (Ohio, Pennsylvania, Alabama).

Frequently Asked Questions

What is clinical trial NCT03826030 about?

NCT03826030 is a clinical study titled "Transcranial Direct Current Stimulation for Post-stroke Motor Recovery". This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation technique is called transcranial direct current stimulation (tDCS). The treatment uses direct currents to stimulate spec...

What is the current status of trial NCT03826030?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2019-09-01. Estimated completion is 2024-09-19.

What conditions does trial NCT03826030 study?

This clinical trial studies the following conditions: Stroke, Ischemic, Motor Activity, Upper Extremity Paralysis.

What interventions are being tested in trial NCT03826030?

The interventions under investigation include: Sham (DEVICE), Low dose tDCS (DEVICE), High dose tDCS (DEVICE), mCIMT (BEHAVIORAL).

Who is sponsoring clinical trial NCT03826030?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03826030 being conducted?

This trial has 14 study locations across Alabama, California, District of Columbia, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke, Ischemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03826030's enrollment target sits among peer trials

129 11th of 33 higher than 23 of 33 other Stroke, Ischemic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke, Ischemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03619850 · 129 participants · Phase 3

    A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

  • NCT05704361 · 129 participants · Phase 1

    A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

  • NCT05919849 · 129 participants · Phase 1

    Supporting Parents in Affirming Their Children's Experiences of Stigma

  • NCT06313749 · 129 participants · NA

    Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03826030, the US trial registry maintained by the National Library of Medicine. NCT03826030 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.